{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:07:12Z","timestamp":1791450432315,"version":"4.3.3"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T00:00:00Z","timestamp":1469750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24 career award (NIAMS: grant # AR053593)"],"award-info":[{"award-number":["K24 career award (NIAMS: grant # AR053593)"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0160221","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T16:44:50Z","timestamp":1469810690000},"page":"e0160221","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":398,"title":["Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports"],"prefix":"10.1371","volume":"11","author":[{"given":"Noha","family":"Abdel-Wahab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsin","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,7,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2051-1426-1-12","article-title":"Primer on tumor immunology and cancer immunotherapy","volume":"1","author":"TJ Harris","year":"2013","journal-title":"J Immunother Cancer"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/ajt.12834","article-title":"Understanding the CD28\/CTLA-4 (CD152) pathway and its implications for costimulatory blockade","volume":"14","author":"D Gardner","year":"2014","journal-title":"Am J Transplant"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"DM Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/eji.201344413","article-title":"Inhibitory receptors as targets for cancer immunotherapy","volume":"45","author":"ME Turnis","year":"2015","journal-title":"Eur J Immunol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies","volume":"65","author":"DB Page","year":"2014","journal-title":"Annu Rev Med"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"FS Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"ref7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/14737140.2015.1074862","article-title":"Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma","volume":"15","author":"E Faghfuri","year":"2015","journal-title":"Expert review of anticancer therapy"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00262-014-1650-8","article-title":"Immune checkpoint combinations from mouse to man","volume":"64","author":"M Ai","year":"2015","journal-title":"Cancer immunology, immunotherapy: CII"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"A Bertrand","year":"2015","journal-title":"BMC medicine"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"TW Chen","year":"2015","journal-title":"Ann Oncol"},{"issue":"43","key":"ref11","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1038\/onc.2015.5","article-title":"Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience","volume":"34","author":"J Gao","year":"2015","journal-title":"Oncogene"},{"key":"ref12","first-page":"1200","article-title":"Immune related adverse events (irAEs) and overall survival (OS) in patients (pts) with melanoma (mel) treated outside of a clinical trial with ipilimumab (ipi) at memorial sloan kettering (MSK)","volume":"1169","author":"TZ Horvat","year":"2014","journal-title":"Pigment Cell and Melanoma Research"},{"key":"ref13","article-title":"Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center","author":"DB Johnson","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"CJ Voskens","year":"2013","journal-title":"PLoS ONE"},{"issue":"18","key":"ref15","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"JS Weber","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"ref16","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"JS Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","article-title":"Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma","volume":"38","author":"MMK Chan","year":"2015","journal-title":"Journal of Immunotherapy"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"F Fadel","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"BL Goldstein","year":"2014","journal-title":"Arthritis rheumatol"},{"key":"ref20","first-page":"16","article-title":"Delayed autoimmune effects in patients treated with antibodies against the checkpoint inhibitor PD1","volume":"11","author":"P Hanrahan","year":"2013","journal-title":"JDDG\u2014Journal of the German Society of Dermatology"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1017\/S0317167100007939","article-title":"Autoimmune inflammatory myopathy after treatment with ipilimumab","volume":"36","author":"G Hunter","year":"2009","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"S Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","article-title":"Guidelines for submitting adverse event reports for publication","volume":"30","author":"WN Kelly","year":"2007","journal-title":"Drug safety"},{"key":"ref24","unstructured":"IBM Corp. Released 2012. IBM SPSS Statistics for Windows VA NIC."},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1188\/11.CJON.393-403","article-title":"Atypical clinical response patterns to ipilimumab","volume":"15","author":"B Ledezma","year":"2011","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy","volume":"373","author":"M Nishino","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"O Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"ref28","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM)","volume":"31","author":"O Hamid","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"ref29","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"MA Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"26","key":"ref30","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"SL Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"SL Topalian","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/PPO.0000000000000186","article-title":"Managing Adverse Events With Immune Checkpoint Agents","volume":"22","author":"R Dadu","year":"2016","journal-title":"Cancer journal"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"JM Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"28","key":"ref34","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"TZ Horvat","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"ref35","article-title":"Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma","volume":"29","author":"RA Ibrahim","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","article-title":"Principles and use of anti-CTLA4 antibody in human cancer immunotherapy","volume":"18","author":"KS Peggs","year":"2006","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"ref37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1089\/cbr.2010.0865","article-title":"Releasing the brake on the immune system: ipilimumab in melanoma and other tumors","volume":"25","author":"A Tarhini","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"issue":"2","key":"ref38","first-page":"265","article-title":"Dysmicrobism, Inflammatory Bowel Disease and Thyroiditis: Analysis of the Literature","volume":"29","author":"G Tomasello","year":"2015","journal-title":"Journal of biological regulators and homeostatic agents"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0160221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:07:36Z","timestamp":1540336056000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0160221"}},"subtitle":[],"editor":[{"given":"Hiroyoshi","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,7,29]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0160221","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726585846.793555466","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,29]]}}}